Evaluation of drugs used in the prophylaxis of neonatal conjunctivitis.
Administration of silver nitrate 1% solution into the eyes of the newborn has proven effective in the prophylaxis of gonococcal neonatal conjunctivitis. Silver nitrate, however, is not active against Chlamydia trachomatis, the most common cause of neonatal conjunctivitis. Also, silver nitrate commonly is associated with substantial chemical irritation. For these reasons, alternative agents are receiving increasing attention. Recently, erythromycin 0.5% and tetracycline 1% ophthalmic ointments were recommended by the Centers for Disease Control Venereal Disease Control Division for prophylaxis of neonatal conjunctivitis. Erythromycin has proven at least as effective as silver nitrate for gonococcal prophylaxis, can prevent chlamydial conjunctivitis in infants born to Chlamydia-positive mothers, and is associated with minimal complications. Clinical studies, however, demonstrating significant differences between erythromycin and tetracycline ophthalmic ointments are lacking. Well-controlled clinical studies comparing silver nitrate, erythromycin, and tetracycline prophylaxis are needed to determine the relative effectiveness of these agents.
D002690:Chlamydia Infections / Q000150:complications / Q000517:prevention & control; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006069:Gonorrhea / Q000150:complications / Q000517:prevention & control; D006801:Humans; D007231:Infant, Newborn; D009878:Ophthalmia Neonatorum / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D012835:Silver Nitrate / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D004917:Erythromycin; D012835:Silver Nitrate; D013752:Tetracycline